adhesion G protein-coupled receptor E5Genealiases: CD97 · TM7LN1
Q-omics provides the consensus-scored ADGRE5 profile across patient tissues and cancer cell-line models. ADGRE5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ADGRE5 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ADGRE5 protein abundance shows 32,375 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where ADGRE5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRE5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRE5 survival associations across molecular data types. ADGRE5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRE5 RNA expression–survival associations across cancer types. High ADGRE5 expression shows unfavorable associations in ACC, UVM, MESO and LIHC, but favorable associations in SKCM and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ADGRE5 RNA expression.
This table summarizes ADGRE5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ADGRE5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRE5 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, KIRP and THCA. The KIRC box plot shows higher ADGRE5 RNA expression in tumor versus normal tissue (log2 FC = +1.467, t-test p < 0.001).
This table shows molecular features associated with ADGRE5 in patient tissues and cancer cell lines. In patient samples, ADGRE5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRE5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
